Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 18/20 | 0.81 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.81 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.81 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.81 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4698127 | 0.90 | OPRM1 (1.00) | OPRM1OPRK1OPRD1KCNH2ARRB1 | |
| SCHEMBL5471369 | 0.86 | OPRM1 (0.69) | OPRM1OPRK1OPRD1KCNH2 | |
| SCHEMBL4697908 | 0.85 | OPRM1 (0.87) | OPRM1OPRK1OPRD1KCNH2ARRB1 | |
| SCHEMBL4698672 | 0.84 | OPRM1 (0.85) | OPRM1OPRK1OPRD1KCNH2ARRB1 | |
| SCHEMBL5851614 | 0.84 | OPRM1 (0.68) | OPRM1OPRK1OPRD1KCNH2 | |
| SCHEMBL5852181 | 0.82 | OPRM1 (0.64) | OPRM1OPRK1OPRD1KCNH2 | |
| SCHEMBL6487839 | 0.82 | OPRM1 (0.64) | OPRM1OPRK1OPRD1KCNH2 | |
| SCHEMBL4700297 | 0.81 | OPRM1 (0.68) | OPRM1OPRK1OPRD1KCNH2ARRB1 | |
| Citric Acid SCHEMBL4698111 | 0.81 | OPRM1 (0.81) | OPRM1OPRK1OPRD1KCNH2ARRB1 | |
| SCHEMBL5456650 | 0.81 | OPRM1 (0.70) | OPRM1OPRK1OPRD1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008075162-A2 | SELECTIVE MU OPIOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF FEMALE SEXUAL DYSFUNCTION | PFIZER LIMITED (GB) | 2008-06-26 | — | — | WO | claimed |
| EP-1440059-B1 | 3-AZABICYCLO(3.1.0)HEXANE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2008-04-16 | — | — | EP | claimed |
| US-7049335-B2 | 3-azabicyclo[3.1.0]hexane derivatives | PFIZER INC. (US) | 2006-05-23 | — | — | US | claimed |
| US-20030087898-A1 | 3-azabicyclo[3.1.0]hexane derivatives | PFIZER INC. | 2003-05-08 | — | — | US | claimed |
| WO-2008075162-A2 | SELECTIVE MU OPIOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF FEMALE SEXUAL DYSFUNCTION | PFIZER LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
| EP-1440059-B1 | 3-AZABICYCLO(3.1.0)HEXANE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2008-04-16 | — | — | EP | disclosed |
| US-20070054950-A1 | 3-Azabicyclo[3.1.0]hexane derivatives | PFIZER INC. | 2007-03-08 | — | — | US | disclosed |
| US-7153976-B2 | Purification process for an azabicyclo[3.1.0]hexane compound | PFIZER INC. (US) | 2006-12-26 | — | — | US | disclosed |
| US-7049335-B2 | 3-azabicyclo[3.1.0]hexane derivatives | PFIZER INC. (US) | 2006-05-23 | — | — | US | disclosed |
| US-20050171178-A1 | 3-Azabicyclo[3.1.0]hexane derivatives | PFIZER INC | 2005-08-04 | — | — | US | disclosed |
| US-20050075387-A1 | Process for preparing an azabicyclo[3.1.0] hexane compound | PFIZER INC | 2005-04-07 | — | — | US | disclosed |
| EP-1440059-A1 | 3-AZABICYCLO(3.1.0)HEXANE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | Pfizer Products Inc. (US) | 2004-07-28 | — | — | EP | disclosed |
| US-20030087898-A1 | 3-azabicyclo[3.1.0]hexane derivatives | PFIZER INC. | 2003-05-08 | — | — | US | disclosed |
| WO-2003035622-A1 | 3-AZABICYCLO (3.1.0) HEXANE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087898-A1 | 3-azabicyclo[3.1.0]hexane derivatives | OPRD1, OPRM1, OPRK1 | OPRM1 2/4885OPRK1 3/4885OPRD1 1/4885 |
| US-20050171178-A1 | 3-Azabicyclo[3.1.0]hexane derivatives | OPRD1, OPRM1, OPRK1 | OPRM1 2/4885OPRK1 3/4885OPRD1 1/4885 |
| US-20070054950-A1 | 3-Azabicyclo[3.1.0]hexane derivatives | OPRD1, OPRM1, OPRK1 | OPRM1 2/4885OPRK1 3/4885OPRD1 1/4885 |
| US-20050075387-A1 | Process for preparing an azabicyclo[3.1.0] hexane compound | AZI2, CYP1B1, CYP4B1 | OPRM1 2847/4885OPRK1 3668/4885OPRD1 1930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.